Thomas Ybert, CEO of DNA Script
0:00 SYNTAX - democratizing DNA synthesis
8:00 Why now? Why did it take so long?
12:52 How disruptive is this?
18:30 EDS to replace chemical synthesis
22:05 Any success with long DNA?
26:22 Challenges to scaling
DNA is a multibillion-dollar industry in 2021 and satisfies many life science applications, including drugs, reagents, siRNA, PCR, diagnostics, synthetic biology, and many others. Enzymatic DNA synthesis, or EDS, is a new approach to manufacturing DNA that is much more efficient and user-friendly and could disrupt the current market.
Thomas Ybert is the CEO of DNA Script which is out with a new benchtop enzymatic DNA synthesizer called SYNTAX. He says in contrast to old chemical synthesizers, the new “DNA printer” takes virtually no expertise to run and will return much of the current business from service back to the old model where biologists make their own, having the power to “go from design to results in less than 24 hours.”
“[Biologists] are programming biological systems. DNA is the programming code. And you want this design-build-test cycle to go as fast as possible. It’s very clear that the next revolution will be from the life sciences. And we want to enable people to design-build-test super quickly.”
Investors appear happy with the company, just pouring in $165 million last month. The SYNTAX system is available now. With all that hassle of chemical synthesis cleared away by this new easy-to-use technology, will researchers and others return to making their own DNA?